European Journal of Biomedical and Pharmaceutical Sciences

SEVERITY ASSESSMENT OF ADVERSE DRUG REACTION AND QUALITY OF LIFE OF DYSLIPIDEMIA PATIENTS ON ATORVASTATIN OR ROSUVASTATIN V/S CONTROLLED.

Shilpa Sah*, Dr. Yusra Ahmad and Dr. Puneet Dhameja

ABSTRACT

Background: Adverse drug reaction and quality of life is most important in terms of patient health, by analyzing these two parameters there must be improvement in dyslipidemia patients. Method: Rosuvastatin and Atorvastatin were used for the study. A total no. of 60 patients with dyslipidemia was taken and age group of 30-90 years. Total patient were divided into two groups. Atorvastatin drug given to group I and Rosuvastatin to group II. Study was carried out for six months.Inclusion criteria: Dyslipidemia, Age above 18, both sexes, Patient having multiple risk factors for heart diseases. Exclusion Criteria: History of myalgia, Hyersensitive to Atorvastatin or Rosuvastatin, Pregnancy and lactation, Woman on oral contraceptives, patient with abnormal liver function and abnormal renal function. While taking patient history, Questionnaire for quality of life has been prepared as per W.H.O guidelines.SF-36 was followed for both groups. Result: From total 60 patients, 70% were male and 30% were female. Total percentage of adverse drug reaction in group I, mild (51.72), moderate (44.8), severe (3.45) and for group II, mild (6.89), moderate (86.2), severe (6.89) and overall adverse drug reactions in percentage by both drugs were 58.61 for mild, 13.1 moderate and 10.34 severe. Quality of life was better shown in group II (Rosuvastatin) than group I (Atorvastain) and adverse drug reaction was shown less in group I (Atorvastatin). Conclusion: In future, study can be done on the basis of molecular and biochemical mechanisms of myopathy and rhabdomyolysis by statins as well as on Atherogenic Dyslipidemia.

Keywords: Quality of Life, Adverse Drug Reaction, Dyslipidemia.